Pfizer lawsuit could clear path for biosimilars

Pfizer lawsuit could clear path for biosimilars

Source: 
Medical Marketing and Media
snippet: 

As more biosimilars enter the market, makers of these complex, copycat drugs have struggled to compete with their branded equivalents. But an antitrust action involving Pfizer and Johnson & Johnson, still in its early stages, could change that.